Abstract: A vehicle control method includes: acquiring information on acceleration, information on rotational speed of a drive wheel, and information on driving force; after a dropping state where a calculated speed indicative of a vehicle body speed calculated from the rotational speed is less than an estimated speed indicative of a vehicle body speed in a front-rear direction estimated from the acceleration has transitioned to a non-dropping state and a holding period in which the non-dropping state is held has passed, determining whether or not a reset condition to reset the estimated speed is satisfied; when the reset condition is satisfied, determining whether or not the driving force is less than a threshold value; and when the driving force is less than the threshold value, resetting the estimated speed and setting a current value of the calculated speed to a vehicle body initial speed used for estimating the estimated speed.

Abstract: A traction controller for an electric vehicle according to the present disclosure calculates a first target torque and a second target torque. The first target torque is a motor torque for achieving a target rotational speed calculated based on a target slip. The second target torque is a motor torque for achieving a target driving force set based on an estimated friction coefficient of a road surface and a ground contact load. The traction controller determines an arbitration target torque with the first target torque as a required value and the second target torque as a constraint condition, and controls the motor based on the arbitration target torque.

Abstract: An electrified vehicle disclosed in the present specification includes: a motor configured to rotate a drive wheel of the electrified vehicle; a sensor configured to detect a motor rotation number that is the number of rotations of the motor; and a control device configured to perform feedback control of the motor rotation number based on a value detected by the sensor. The control device is configured to perform during the feedback control a process of extracting a vibration component in a predetermined frequency band from the value detected by the sensor, a process of calculating an integrated value by integrating the extracted vibration component for a predetermined period, and a process of determining whether the calculated integrated value falls within a predetermined abnormal range.

Abstract: A braking capacity decrease determining device including a brake ECU is applied to a vehicle including wheel speed sensors and a brake device. The brake ECU performs a first determination process of determining whether a temporary braking decrease determination condition is satisfied for each of a plurality of wheels provided on the vehicle. The brake ECU additionally performs a second determination process of determining whether there are both a wheel for which the temporary braking decrease determination condition is satisfied and a wheel for which the temporary braking decrease determination condition is not satisfied out of the plurality of wheels and determining that a braking capacity of the brake device has decreased when it is determined that there are both a wheel for which the temporary braking decrease determination condition is satisfied and a wheel for which the temporary braking decrease determination condition is not satisfied.

Abstract: A braking capacity decrease determining device including a brake ECU is applied to a vehicle including wheel speed sensors and a brake device. The brake ECU performs a first determination process of determining whether a temporary braking decrease determination condition is satisfied for each of a plurality of wheels provided on the vehicle. The brake ECU additionally performs a second determination process of determining whether there are both a wheel for which the temporary braking decrease determination condition is satisfied and a wheel for which the temporary braking decrease determination condition is not satisfied out of the plurality of wheels and determining that a braking capacity of the brake device has decreased when it is determined that there are both a wheel for which the temporary braking decrease determination condition is satisfied and a wheel for which the temporary braking decrease determination condition is not satisfied.

Abstract: Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier.

Abstract: Disclosed is a moisturizing agent comprising a copolymer represented by formula (1). [In formula (1), A represents a substituent containing an oligosaccharide composed of 2 to 6 monosaccharide molecules bound to each other; B represents a group represented by formula (2); m and n represent numbers which meet the following equation m:n=9:1 to 1:9; and Z represents a hydrogen group, a methyl group or an ethyl group.

Abstract: Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a method for preparing adoptive immune cells comprising the following steps of a) obtaining mammalian antigen-presenting associated cells; b) culturing the resulting cells in a culture vessel coated with a sugar chain-containing polymer; and c) detaching the cells by shaking the culture vessel without treating the cells with enzyme and without using a cell detaching tool; adoptive immune cells obtained by this preparing method; a culture vessel coated with a sugar chain-containing polymer for use in this preparation method; a kit for preparing an adoptive immune cell vaccine; and a method and a medicine for treating a malignant tumor, type I diabetes, atopic allergic diseases or infections using the adoptive immune cells.

Abstract: It is an object of the present invention to provide a contact lens solution that imparts stable hydrophilicity even to a surface of a contact lens having strong water repellency. There was prepared a contact lens solution comprising a copolymer of N-p-vinylbenzyl-D-lactonamide and at least one monomer copolymerizable therewith. The copolymer is present in the solution in an amount of 0.0001 to 5 w/v %.

Abstract: The present invention provides a method for preparing adoptive immune cells comprising the following steps of a) obtaining mammalian antigen-presenting associated cells; b) culturing the resulting cells in a culture vessel coated with a sugar chain-containing polymer; and c) detaching the cells by shaking the culture vessel without treating the cells with enzyme and without using a cell detaching tool; adoptive immune cells obtained by this preparing method; a culture vessel coated with a sugar chain-containing polymer for use in this preparation method; a kit for preparing an adoptive immune cell vaccine; and a method and a medicine for treating a malignant tumor, type I diabetes, atopic allergic diseases or infections using the adoptive immune cells.

Abstract: A time division multiplex transmission apparatus which transmits low-speed data and telegraph signals of a maximum of n.times.m channels as high-speed data in a multiplexed manner based on a time division system. The apparatus also separates received high-speed data into low-speed data and telegraph signals.

Abstract: A process for producing a resin having a high heat resistance with a high polymerization conversion by emulsion-polymerizing .alpha.-methylstyrene (AMS), methyl methacrylate (MMA) and acrylonitrile (AN), characterized in that the polymerization is conducted in two steps; A monomer mixture consisting of 60-85% by weight of AMS, 2-30% by weight of MMA and 5-20% by weight of AN is subjected to copolymerization in the first step until 25-85% by weight, based on the weight of the final copolymer, of a copolymer is formed, and in the second step, at least one monomer of the above three monomers is added to the polymerization system to adjust the composition ratio of the three monomers in the polymerization system so as to fall in the region surrounded by the lines connecting points A, B, C, D and E in the triangular coordinate graph indicating the quantitative relationship of the three monomers, and the resulting monomer mixture is subjected to polymerization conditions to complete the polymerization.